MEXICO CITY Back in 2019, while she worked for the biotech Regeneron Pharmaceuticals, Claudia Gonzaga heard a rumor that thrilled her. The company would begin sequencing and analyzing the DNA of 150,000 people from Mexico City, thanks to a research collaboration with the University of Oxford.
As the only Mexican geneticist at Regeneron, Gonzaga saw this as a unique opportunity. She had previously tried to convince her colleagues to sequence the genomes of people from Mexico, where researchers have found a stunning amount of human genetic diversity, but to no avail. The new partnership meant she would be able to resume her plans. I was so pleased, she said.
She was similarly surprised when she later learned that Oxford researchers had very much tried to keep this a Mexican study. While Oxford, not a Mexican institution, had physical custody of all the samples, Mexican epidemiologists had actively participated in almost every step of the research, and once the genetic data were ready, the Oxford team would make them public and offer rapid, free, and preferential access to Mexican scientists.
advertisement
It went against the long history of parachute science or helicopter research when researchers from wealthier nations visit low- and middle-income countries to collect data and samples, analyze them back at home, and publish the results with little or no involvement of local scientists.
Gonzaga left the company for academia in 2020 and went back to Mexico. She hasnt gotten her hands on the data yet, though shes already planning what shell do with them, such as hunting for genetic variants closely linked to diseases like breast cancer and calculating how frequent they are in Mexicans. And she is pushing to have a physical copy of the genetic biobank hosted at her institution.
advertisement
I have many ideas of things we can do, said Gonzaga, now a genomicist studying genetic disorders at the International Laboratory for Human Genome Research of the National Autonomous University of Mexico (UNAM) in Quertaro. What I need now is having access to the data.
The building and study of massive sets of genetic data from Mexicans is part of a global effort to make genetic collections and biobanks, which are still too white, representative of all humans. Though necessary to achieve that goal, international partnerships pose uncomfortable questions, such as who owns the data, whom to share it with, and what for.
Experts mostly laud the Mexico City project for avoiding the worst sins of parachute science and aiming to strengthen research capacity in the country, though Oxford controls access to the data and Mexican scientists like Gonzaga are still waiting for it. Some experts also warn that, when trying to promote fairer international collaborations and diversify the people they study, local researchers must be careful not to perpetuate the same discrimination they sometimes face, by excluding Mexicos many Indigenous populations from participating actively in research involving their communities.
Lets not forget that exploitation, extractivism, and colonialism also exist [in our countries], said Amaranta Manrique de Lara, a genomicist and bioethicist at the General Hospital of Mexico in Mexico City. In our effort to combat old biases, we may be generating new ones.
In the 1990s, a simple yet ambitious question arose: What is killing Mexicans?
We knew an awful lot about what killed white middle-aged men and women, said Jonathan Emberson, a statistical epidemiologist at the University of Oxford. But there was a real dearth of evidence for everyone else, he added.
To find that data, a group of epidemiologists from Oxford and Mexicos Secretariat of Health teamed up. Between 1998 and 2004, they sent hundreds of trained nurses to the homes of more than 150,000 people in two contiguous districts in Mexico City Iztapalapa and Coyoacn to ask about their health history, measure their vitals, and draw a tube of blood from them. But their blood samples, and the DNA within them, remained largely untouched for about two decades at Oxford. Until 2019, that is, when the team approached Regeneron and the pharmaceutical companies AstraZeneca and AbbVie for help with sequencing and analyzing the genetic material.
It was then that Gonzaga first heard about the Mexico City Prospective Study, or MCPS an ongoing project that has followed participants over the years to understand the social, lifestyle, physical, and genetic causes of complex diseases, such as diabetes and obesity. The study resurveyed 10,000 surviving participants between 2015 and 2019.
It really is a waiting game, said Emberson, who is the program leader for the MCPS. You need to wait until, sadly, enough participants have had diseases of interest and you dont get that within just a few years.
In fact, it was not until 2016 that the MCPS published its first major finding. After reviewing the death certificates of participants, the researchers found that those with diabetes had a strikingly worse prognosis than that seen in high-income nations. In Mexico City, it turns out, the rate of death from any cause was almost four times as high among people with diabetes as among those without the disease.
More recently, in a preprint published in late June, the team added to its extensive evidence the genetic sequences for MCPS participants, hoping to find new gene variants associated with diseases. They mostly focused on the exomes, regions that make up the 2% of the human genome that code for proteins, which drug hunters typically mine to uncover disease-linked changes.
With this, the MCPS has become the most extensive genetic study in people outside the U.S., the U.K., or Iceland which together account for over 72% of all participants in genome-wide association studies, known as GWAS, which scientists use to hunt for snippets of DNA that may be linked to a certain disease or trait. Latin Americans make up around 8% of all people on the planet, yet they constitute 0.25% of all these genetic studies, according to the online tracker GWAS Diversity Monitor.
The MCPS genetic sequences have already proven their worth. They were included in a paper, published in Science last year, that discovered rare mutations that inactivated a gene called GPR75, which was associated with protection against weight gain people with these variants tended to weigh about 12 pounds less and face a 54% lower risk of obesity than those without the mutation. (Emberson noted that while MCPS data were a worthwhile addition to the GPR75 paper, the discovery didnt ultimately depend on any of it. Regeneron spokesperson Ella Campbell, however, wrote in an email to STAT that they were needed to ensure the discovery held true with different populations.)
Regeneron and AstraZeneca have announced they are developing drug candidates directed against GPR75 to treat obesity. Should a medicine eventually reach market, Campbell wrote, Oxford and Regeneron would be able to share or generate their own intellectual property, according to their collaboration agreement.
As the only Mexican institution in the MCPS, UNAM equally shares any intellectual property rights with Oxford. We both own the information, said Jess Alegre Daz, a medical epidemiologist at UNAMs Faculty of Medicine in Mexico City and one of the three Mexican principal investigators involved in the MCPS. Were Mexicans studying Mexicans.
Elida Fernndez, a lawyer at UNAM, said a research agreement between both universities was signed in early August with the purpose of resurveying surviving participants. Among other things, the contract, which STAT reviewed, dictates that both UNAM and Oxford can use the samples and data and that the results of the research including all intellectual property rights, data, discoveries, and patents will be shared between both institutions.
The vast amount of genetic data pouring out of the MCPS has some Mexican geneticists salivating to get their hands on it.
In 2016, Andrs Moreno Estrada, a human population geneticist at Mexicos National Laboratory of Genomics for Biodiversity in Irapuato, and colleagues launched the MX Biobank project, which sequenced the DNA of about 6,000 people from across the country, including many from Indigenous communities and rural areas. Though the biobank also works in partnership with Oxford, Moreno Estrada said that they negotiated to keep the guts of the project in Mexico to build its research capacity the samples are hosted in a Mexican institution, the bulk of the genomic analysis is led by the Mexican research team, and many of the projects former students are continuing their careers studying the data they generated.
He recently approached the MCPS researchers in hopes to collaborate and share their respective datasets with each other. We dont have their numbers, he said, referring to the size of the MCPS dataset. They are discovering things that we cant.
He might need to wait a bit longer.
Regeneron has launched an online browser that includes the genetic variation found across all 150,000 participants, making it freely accessible to anyone. But the browser, for now, is not very useful, said Gonzaga. It lacks key information that makes it difficult to know whether a disease-linked variant is present in 100 or 10,000 people, for example.
So far, the MCPS research group at Oxford holds the custody of the studys samples and data. It happens to be that this process has been managed at Oxford at the moment, Emberson said. But, I mean, maybe in the future it will be done separately or jointly with UNAM. The recently signed agreement may allow that.
Still, the MCPS has made important progress to support Mexican scientists and strengthen local research capacity. Oxford has trained staff in Mexico and paid for courses and short-term research placements, said Emberson. And as soon as the data are clean, Mexican researchers will have free and preferential access to it for a period of two years. Researchers based elsewhere in the world will need to pay up to 2,500 (about $3,000) to receive the data.
The policy feels like a step in the right direction, said Mashaal Sohail, an evolutionary geneticist at UNAMs Center for Genomic Sciences in Cuernavaca. And one thats not very common. Even within Mexico, she said, people are generating data and not sharing it with other academic groups.
Even if international partnerships move toward fairer conditions, some scientists warn that may not be enough.
Stripping [genomic science] of its colonialism, hierarchy, and structural violence has to be an everyday task, said Jocelyn Che Santiago, a Binniz genomic scientist at UNAM in Mexico City (the Binniz, also known as Zapotec, are one of Mexicos 68 Indigenous groups.) If we are not going to discuss the colonialism [aspect] of our research, then whats the point?
For decades, Mexico has tried to guard the genetic data of its citizens. In 2008, Congress passed a national law that embraced the idea of genomic sovereignty, a concept that aims to protect Mexican DNA by itself absurdly difficult to define, critics say from foreign interests. And many researchers saw it as a way to break this relationship between us Mexicans as suppliers of samples, and foreign scientists as the ones who analyzed [them], said Ernesto Schwartz-Marn, an ethnographer who probes the interaction between race and genomics at the University of Exeter, U.K.
But the law has made little difference. Genomic sovereignty is a bulls term, Schwartz-Marn said. Its impossible to execute because theres no way to say what the Mexican genome is or looks like. And theres no consensus about who is supposed to guard it.
In 2010, the state of Nayarit included a provision in its constitution on genomic sovereignty. Schwartz-Marn indirectly participated in its design, and suggested that the language enable Indigenous peoples to protect their own genetic data. When we tried to get this into the draft, he said, thats exactly what [legislators] erased.
The incident is a window into a double standard in Mexico, said Manrique de Lara. When studying Indigenous populations or other groups, such as people who live with a disability or disease, Mexican scientists often do a lot of this parachute research we so often criticize. And rare is the case when study participants see any benefits from the science, she added.
The way to counter that is by creating fairer collaborations, Che Santiago said, where participants have an active role in the research such as deciding what questions to ask, how to ask them, and who has custody over the data. That we are no longer part of the menu, she said, but part of the table where decisions are made.
Its something thats happening elsewhere. In Australia, the National Centre for Indigenous Genomics is governed by a majority-Indigenous board, and has approached communities to ask what they wish to do with their samples. In Chile, recent efforts to explain the uses and limitations of genetics led scientists and Indigenous people to come together in a three-day workshop. And in countries like the U.S. and Canada, the Summer Internship for Indigenous peoples in Genomics (also known as SING) have trained Indigenous participants in genomics and its ethical implications.
Such changes are coming slowly in Mexico. Manrique de Lara and colleagues who teach future geneticists at UNAMs Center for Genomic Sciences have started to incorporate parachute science, scientific colonialism, and other bad practices into the syllabus of their classes.
If we do our job right, she said, well be seeing this internal change in the next generation of researchers.
Correction: This story has been updated to say that the MCPS has become the most extensive genetic study in people outside the U.S., the U.K., or Iceland.
Read this article:
A team of Oxford and Mexican researchers want to diversify genomic databases. Can they end 'parachute science,' too? - STAT
- CRISPR: A game-changing genetic engineering technique - January 4th, 2023
- Genetic Counseling Online Course - School of Medicine Columbia ... - January 4th, 2023
- Genetics & Medicine - Site Guide - NCBI - National Center for ... - December 27th, 2022
- Lilly, ProQR to expand genetic medicine development agreement - December 27th, 2022
- Central Dogma and Genetic Medicine - HHMI BioInteractive - November 24th, 2022
- Social, Environmental, Cognitive, and Genetic Influences on the Use of ... - November 24th, 2022
- Genetically modified food controversies - Wikipedia - October 29th, 2022
- BSGM - The British Society for Genetic Medicine - October 13th, 2022
- Genetic and Genomic Medicine - Nationwide Children's Hospital - October 13th, 2022
- Carrier Screening for Genetic Conditions | ACOG - October 13th, 2022
- New NHS genetic testing service could save thousands of children in England - The Guardian - October 13th, 2022
- Vertex, after setbacks, moves forward with second-generation rare disease drug - BioPharma Dive - October 13th, 2022
- Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer - Yahoo Finance - October 13th, 2022
- Metagenomi Announces Participation in October Investor and Industry Conferences - Business Wire - October 4th, 2022
- NovaSeq X machines will make genetic analysis even faster and cheaper - Mezha.Media - October 4th, 2022
- ORYZON to Give Updates on Corporate Progress in October - BioSpace - October 4th, 2022
- e-therapeutics: Fundraise of 13.5 million - BioSpace - October 4th, 2022
- The inheritance of hope curing genetic heart disease now within grasp - British Heart Foundation - October 4th, 2022
- MS Genetic Counseling | Ohio State College of Medicine - September 16th, 2022
- Genetic Counselor - Mayo Clinic College of Medicine & Science - September 16th, 2022
- UCLA researcher awarded National Academy of Medicine prize for work on genetics of autism - Newswise - September 16th, 2022
- Medical research doesn't serve everyone. This effort hopes to build one of the most diverse health databases ever - Colorado Public Radio - September 16th, 2022
- Precision Medicine Offers Hope for More Targeted Rash Diagnosis and Treatment - Dermatology Times - September 16th, 2022
- Redmond firefighters to 'Fill the Boot' for Muscular Dystrophy Association - KTVZ - September 16th, 2022
- Why Monkeypox Wasnt Another COVID-19 - FiveThirtyEight - September 16th, 2022
- Endometriosis Researchers One Step Closer to Diagnosing Condition With Menstrual Blood - Business Wire - September 16th, 2022
- The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List - The Medicine Maker - September 16th, 2022
- Humans evolved with their microbiomes like genes, your gut microbes pass from one generation to the next - The Conversation - September 16th, 2022
- When to Use Targeted Therapy for Iodine-Refractory Thyroid Cancer - Targeted Oncology - September 16th, 2022
- Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences - PR Newswire - September 16th, 2022
- CRISPR is 10: A decade of gene editing refinements presents new ways to address agricultural diseases thought to be incurable - Genetic Literacy... - September 16th, 2022
- Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for ... - The Bakersfield Californian - September 8th, 2022
- 'Record' Gains in Bringing Research Closer to the Patient - Applied Clinical Trials Online - September 8th, 2022
- Metagenomi Announces Participation in September Investor and Industry Conferences - Business Wire - September 8th, 2022
- Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy - Yahoo Finance - September 8th, 2022
- Studies Reveal Aggressive Prostate Cancer Linked to Ancestral Heritage - DocWire News - September 8th, 2022
- Lonza and Touchlight collaboration will expands customer's access to DNA - Labiotech.eu - September 8th, 2022
- Genetic variants in miR-145 gene are associated with the risk of asthma in Taiwan | Scientific Reports - Nature.com - September 8th, 2022
- Elderly are more affected by COVID brain fog, but 'cognitive rehab' could be an effective treatment - Genetic Literacy Project - September 8th, 2022
- A therapy found to improve cognitive function in patients with Down syndrome - EurekAlert - September 8th, 2022
- Ovid turns to gene therapy startup to restock drug pipeline - BioPharma Dive - August 30th, 2022
- Morris Animal Foundation Golden Retriever Lifetime Study Celebrates 10 Years - PR Newswire - August 30th, 2022
- Immortal jellyfish genes identified that may explain their long lives - New Scientist - August 30th, 2022
- Walk Again Or Stop Blindness. How Gene Therapy Is Revolutionizing Medicine - Nation World News - August 30th, 2022
- ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene... - August 30th, 2022
- Therapeutic Effects of Tretinoin | JIR - Dove Medical Press - August 30th, 2022
- Physical Activity May Have a Stronger Role than Genes in Longevity - Newswise - August 30th, 2022
- BridgeBio, Baylor College of Medicine to Collaborate on Genetic Disease ... - August 22nd, 2022
- New $2.8-million gene therapy becomes most expensive medicine in history - New Atlas - August 22nd, 2022
- Molecular Map Reveals Insights Into the Genetic Drivers of CLL - The ASCO Post - August 22nd, 2022
- Biopharmaceutical Company Expands Clinical Trials On Texas A&M-Developed Angelman Syndrome Treatment - Texas A&M University Today - August 22nd, 2022
- Restrictive abortion laws are limiting the options parents have after receiving genetic test results, experts say - Yahoo News - August 22nd, 2022
- Marketing and Industry Trends Influencing Precision Medicine in 2022 - Healthcare Tech Outlook - August 22nd, 2022
- expert reaction to study investigating use of genetic risk score for prostate cancer in men with lower urinary tract symptoms to predict diagnosis -... - August 22nd, 2022
- As the Smithsonian wraps a genome exhibit, leaders in the field reflect - STAT - August 22nd, 2022
- Why some people suffer more from COVID-19 than others - EurekAlert - August 22nd, 2022
- Q3 2022 Earnings Forecast for LogicBio Therapeutics, Inc. Issued By William Blair (NASDAQ:LOGC) - Defense World - August 22nd, 2022
- Next generation patient avatars: Expanding the possibilities with MicroOrganospheres - EurekAlert - August 22nd, 2022
- Masters Program in Genetic Counseling - Perelman School of Medicine at ... - August 14th, 2022
- Admissions | Master's Program in Human Genetics & Genetic Counseling ... - August 14th, 2022
- The Silver Lining Of Innovation in Genetic Medicine - Pharmaceutical Executive - August 14th, 2022
- Genetics Team Serves as Go-to for Mom of Son With Extremely Rare Disorder - Stanford Medicine Children's Health Blog - Stanford Children's Health - August 14th, 2022
- UI professor receives grant from National Institutes of Health - Iowa Now - August 14th, 2022
- Lilly's Taltz (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience - PR Newswire - August 14th, 2022
- Research Roundup: 21 Genes Linked to Increased Risk of Alzheimer's and More - BioSpace - August 14th, 2022
- Personalised medicine made in hospitals can revolutionise the way diseases are treated the challenge now will be implementing it - The Conversation... - August 14th, 2022
- Beyond Paxlovid for covid-19: The hunt for better covid medications - Grid - August 14th, 2022
- PVM to Play Role in Research on New Patent-pending Method to Mass-produce Antitumor Cells to Treat Blood Diseases and Cancer - Purdue University - August 14th, 2022
- Analyzing Kiromic BioPharma (NASDAQ:KRBP) and LogicBio Therapeutics (NASDAQ:LOGC) - Defense World - August 14th, 2022
- Corporate America's Abortion Radicalism - The American Conservative - August 14th, 2022
- The aging heart accumulates mutations while losing the ability to repair them - EurekAlert - August 14th, 2022
- Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results - GuruFocus.com - August 5th, 2022
- Population Genetic Testing: Save Lives And Money, While Avoiding Financial Toxicity - Forbes - August 5th, 2022
- Genetic Counselors Scramble Post- Roe to Provide Routine Pregnancy Services without Being Accused of a Crime - Scientific American - August 5th, 2022
- GENERATION BIO CO. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - August 5th, 2022
- Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results - Yahoo Finance - August 5th, 2022
- Researchers discover one of the largest known bacteria-to-animal gene transfer inside a fruit fly - EurekAlert - August 5th, 2022
- Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress - Yahoo Finance - August 5th, 2022
- Medical Student's Crime In Cipolletti: They Found A Man's DNA Under The Victim's Thumb - Nation World News - August 5th, 2022
- A new era: After winding path and safety scares, gene therapy enters the clinic - Sydney Morning Herald - August 5th, 2022